Like other Sirt1 activators, RGZ administration increased Sirt6 expression and phosphorylation levels of LKB1 and AMPK, and provided protection from hepatic steatosis, suggesting that RGZ may act as a Sirt6 activator and a therapeutic strategy for NAFLD. This evidence concerns the gene STK11 and fatty liver disease.